Skip to main content
OpenTrials
Completed

NCT Number: NCT05885269

Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata

Methodology: The 70 patients of age 20 to 50 years presented to the out-patient department of CMH Abbottabad suffering from alopecia areata were enrolled. The non-probability consecutive sampling technique was used. Patient in group-A applied clobetasol propionate 0.05% twice daily, whereas Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. The Patients were assessed at baseline, 4th weeks, 8th week and 12th week after treatment of each session. Hair loss was calculated from SALT score at presentation and on follow-up after 3 months. The degree of response was assessed on the basis of hair re-growth as excellent (>75% re-growth), Marked (51-75% re-growth), moderate (26-50% re-growth), or slight (≤25% re-growth). To determine statistical significance χ2-square test, taking p-value <0.05 as significant, was used.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alopecia Areata Alopecia Hair Diseases Hypotrichosis Skin Diseases Skin and Connective Tissue Diseases

Age range

20 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Danyal Sajjad

Abbottabad, Khyber Pakhtunkhwa, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients age 20 to 50 years
  • Both male and female
  • Duration of illness less than 2 months
  • those who never received any treatment before

Exclusion criteria

  • Patients having duration of alopecia greater than 2 months
  • Atypical alopecia areata i.e., Alopecia universalis etc
  • Hypersensitivity history to topical corticosteroids or tacrolimus
  • patients taking any systemic immune suppression
  • pregnancy/lactation

Treatment and study plan

Group A applied topical Clobetasol Propionate

Drug

Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months

Group B applied topical Tacrolimus

Drug

Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.

Primary outcomes

  1. The degree of response was assessed on The basis of hair regrowth as excellent, marked, moderate or slight.

    Time frame: 6 months

    The degree of response was assessed on the basis of hair regrowth as excellent (>75% regrowth), marked (51-75% regrowth), moderate (26-50% regrowth), or slight (≤25% regrowth)

Sponsors and collaborators

Lead sponsor

Combined Military Hospital Abbottabad

Other

Registry information

Official study title

Comparative Efficacy of Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jun 1, 2023
Registry last updated
Jun 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.